Krystal Biotech (NASDAQ:KRYS) Reaches New 1-Year High – Should You Buy?

Krystal Biotech, Inc. (NASDAQ:KRYS)’s stock price reached a new 52-week high on Friday . The stock traded as high as $213.69 and last traded at $212.6640, with a volume of 137363 shares trading hands. The stock had previously closed at $204.23.

Analyst Upgrades and Downgrades

Several research analysts have commented on KRYS shares. Guggenheim set a $224.00 target price on Krystal Biotech and gave the stock a “buy” rating in a research note on Friday, October 17th. Bank of America lifted their price target on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a report on Friday, October 17th. HC Wainwright reissued a “buy” rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Monday, September 15th. Chardan Capital boosted their target price on shares of Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a report on Wednesday. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $228.14.

Krystal Biotech Trading Up 4.2%

The firm has a market capitalization of $6.17 billion, a price-to-earnings ratio of 31.89 and a beta of 0.65. The firm’s 50-day moving average is $184.93 and its 200 day moving average is $156.29.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $1.54. The firm had revenue of $97.80 million during the quarter, compared to analysts’ expectations of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. Analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Institutional Investors Weigh In On Krystal Biotech

Institutional investors have recently made changes to their positions in the stock. State of New Jersey Common Pension Fund D lifted its position in shares of Krystal Biotech by 45.2% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 15,033 shares of the company’s stock worth $2,066,000 after purchasing an additional 4,682 shares during the period. EP Wealth Advisors LLC acquired a new stake in shares of Krystal Biotech during the first quarter worth $473,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock worth $103,764,000 after buying an additional 365,304 shares during the last quarter. S Squared Technology LLC raised its stake in Krystal Biotech by 2.1% during the first quarter. S Squared Technology LLC now owns 97,215 shares of the company’s stock worth $17,528,000 after buying an additional 2,000 shares during the last quarter. Finally, Tempus Wealth Planning LLC acquired a new position in Krystal Biotech in the second quarter valued at $327,000. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).